Allovir Inc
For the period ended Dec 31, 2024. Filed Mar 7, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 7, 2025
KLRS$1.87-18.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEM ENTS OF CASH FLOWS
| Years Ended December 31, | ||
|---|---|---|
| (in thousands) | 2024 | 2023 |
| Cash flows from operating activities | ||
| Net loss | $(58,769) | $(190,418) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | — | 398 |
| Non-cash lease expense | 145 | 7,893 |
| Non-cash gain on lease termination and remeasurement | (8,872) | — |
| Impairment costs | — | 18,570 |
| Accretion of short-term investment discounts | (1,251) | (3,698) |
| Stock-based compensation expense | 26,347 | 40,779 |
| Changes in operating assets and liabilities: | ||
| Interest receivable | 206 | (49) |
| Prepaid expenses and other current assets and prepaid expenses to related party | 3,229 | 5,614 |
| Other assets | 122 | (900) |
| Income tax payable | — | (128) |
| Accounts payable, accrued expenses, other liabilities and amount due to related party | (28,862) | (2,512) |
| Net cash used in operating activities | (67,705) | (124,451) |
| Cash flows from investing activities | ||
| Purchase of short-term investments | — | (125,827) |
| Maturities of short-term investments | 95,000 | 163,812 |
| Net cash provided by investing activities | 95,000 | 37,985 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock in public offering, net of underwriting discounts, commissions and offering costs | — | 70,169 |
| Proceeds from issuance of stock under the 2020 Employee Stock Purchase Plan | 21 | 326 |
| Net cash provided by financing activities | 21 | 70,495 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 27,316 | (15,971) |
| Cash, cash equivalents, and restricted cash at beginning of period | 90,973 | 106,944 |
| Cash, cash equivalents, and restricted cash at end of period | $118,289 | $90,973 |
| Non-cash investing and financing activities | ||
| Unrealized (loss) gain on available-for-sale securities | $(73) | $406 |
| Reduction of right-of-use asset due to termination and remeasurement | $(2,044) | $(4,904) |
| Supplemental disclosure of cash flows | ||
| Income taxes paid, net of refunds | $— | $220 |
| Years Ended December 31, | ||
| 2024 | 2023 | |
| Cash and cash equivalents | $118,289 | $90,121 |
| Restricted cash | — | 852 |
| Total cash, cash equivalents, and restricted cash | $118,289 | $90,973 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.